Jingcheng Chen, Jiacheng Wang, Kai Li, Yujie Wu, Ziqian Wang, Jin Guo, Zhigang Zhao, Weixing Feng, Shenghui Mei
{"title":"小儿癫痫患者丙戊酸的剂量预测:群体药代动力学模型还是机器学习模型?","authors":"Jingcheng Chen, Jiacheng Wang, Kai Li, Yujie Wu, Ziqian Wang, Jin Guo, Zhigang Zhao, Weixing Feng, Shenghui Mei","doi":"10.1007/s00228-025-03874-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study develops and compares population pharmacokinetics (PopPK) models and machine learning methods, including neural networks, to predict steady-state trough concentrations in pediatric patients and provide improved dosing recommendations.</p><p><strong>Methods: </strong>Valproic acid concentration data were collected from 490 pediatric epilepsy patients treated at Beijing Tiantan Hospital and Beijing Children's Hospital. We developed predictive models employing PopPK, maximum a posteriori Bayesian (MAPB), multiple linear regression (MLR), machine learning (including Random Forest, XGBoost, and LightGBM for feature selection), and neural network techniques. The predictive accuracy of these models was then rigorously tested through external validation using the independent dataset from Beijing Children's Hospital. Upon identifying the optimal model, dosing regimens for various clinical scenarios were derived and presented.</p><p><strong>Results: </strong>Under the same dataset modeling conditions, the original PopPK models showed limited predictive performance. Transforming these models into multiple linear regression enhanced prediction accuracy. Moreover, when prior data was available, the MAPB method significantly boosted prediction performance. Machine learning and neural networks showed higher accuracy, with neural networks achieving an F<sub>30</sub> value above 80%.</p><p><strong>Conclusion: </strong>This study explored model optimization strategies and compared machine learning and neural network models alongside traditional PopPK. It introduced an advanced method to predict drug concentrations and stable trough dosing regimens in pediatric epilepsy treatment, reducing the need for frequent, invasive blood tests in TDM. These improvements enhanced the efficacy and safety of valproic acid therapy for children, supporting the development of personalized treatment plans.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dosing prediction of valproic acid in pediatric patients with epilepsy: population pharmacokinetic model or machine learning model?\",\"authors\":\"Jingcheng Chen, Jiacheng Wang, Kai Li, Yujie Wu, Ziqian Wang, Jin Guo, Zhigang Zhao, Weixing Feng, Shenghui Mei\",\"doi\":\"10.1007/s00228-025-03874-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study develops and compares population pharmacokinetics (PopPK) models and machine learning methods, including neural networks, to predict steady-state trough concentrations in pediatric patients and provide improved dosing recommendations.</p><p><strong>Methods: </strong>Valproic acid concentration data were collected from 490 pediatric epilepsy patients treated at Beijing Tiantan Hospital and Beijing Children's Hospital. We developed predictive models employing PopPK, maximum a posteriori Bayesian (MAPB), multiple linear regression (MLR), machine learning (including Random Forest, XGBoost, and LightGBM for feature selection), and neural network techniques. The predictive accuracy of these models was then rigorously tested through external validation using the independent dataset from Beijing Children's Hospital. Upon identifying the optimal model, dosing regimens for various clinical scenarios were derived and presented.</p><p><strong>Results: </strong>Under the same dataset modeling conditions, the original PopPK models showed limited predictive performance. Transforming these models into multiple linear regression enhanced prediction accuracy. Moreover, when prior data was available, the MAPB method significantly boosted prediction performance. Machine learning and neural networks showed higher accuracy, with neural networks achieving an F<sub>30</sub> value above 80%.</p><p><strong>Conclusion: </strong>This study explored model optimization strategies and compared machine learning and neural network models alongside traditional PopPK. It introduced an advanced method to predict drug concentrations and stable trough dosing regimens in pediatric epilepsy treatment, reducing the need for frequent, invasive blood tests in TDM. These improvements enhanced the efficacy and safety of valproic acid therapy for children, supporting the development of personalized treatment plans.</p>\",\"PeriodicalId\":11857,\"journal\":{\"name\":\"European Journal of Clinical Pharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-07-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Clinical Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00228-025-03874-y\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00228-025-03874-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Dosing prediction of valproic acid in pediatric patients with epilepsy: population pharmacokinetic model or machine learning model?
Purpose: This study develops and compares population pharmacokinetics (PopPK) models and machine learning methods, including neural networks, to predict steady-state trough concentrations in pediatric patients and provide improved dosing recommendations.
Methods: Valproic acid concentration data were collected from 490 pediatric epilepsy patients treated at Beijing Tiantan Hospital and Beijing Children's Hospital. We developed predictive models employing PopPK, maximum a posteriori Bayesian (MAPB), multiple linear regression (MLR), machine learning (including Random Forest, XGBoost, and LightGBM for feature selection), and neural network techniques. The predictive accuracy of these models was then rigorously tested through external validation using the independent dataset from Beijing Children's Hospital. Upon identifying the optimal model, dosing regimens for various clinical scenarios were derived and presented.
Results: Under the same dataset modeling conditions, the original PopPK models showed limited predictive performance. Transforming these models into multiple linear regression enhanced prediction accuracy. Moreover, when prior data was available, the MAPB method significantly boosted prediction performance. Machine learning and neural networks showed higher accuracy, with neural networks achieving an F30 value above 80%.
Conclusion: This study explored model optimization strategies and compared machine learning and neural network models alongside traditional PopPK. It introduced an advanced method to predict drug concentrations and stable trough dosing regimens in pediatric epilepsy treatment, reducing the need for frequent, invasive blood tests in TDM. These improvements enhanced the efficacy and safety of valproic acid therapy for children, supporting the development of personalized treatment plans.
期刊介绍:
The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed.
Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor.
Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves
-a compound that is interesting and new in some basic or fundamental way, or
-methods that are original in some basic sense, or
-a highly unexpected outcome, or
-conclusions that are scientifically novel in some basic or fundamental sense.